BioNTech RNA Pharmaceuticals GmbH v CureVac SE

Link copied
Case Copied 29 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

BioNTech RNA Pharmaceuticals GmbH v CureVac SE [2023] APO 36

Patent Application:                2016251687

Title:RNA containing composition for treatment of tumor diseases

Patent Applicant:                   CureVac SE

Opponent:  BioNTech RNA Pharmaceuticals GmbH

Delegate:  L. F. McCaffery

Decision Date:  16 June 2023

Hearing Date:  11 April 2023, by videoconference

Catchwords:  PATENTS – compositions comprising mRNA – consideration of allowability of amendments under subsections 102(1) and 102(2)(b) – whether the amendments extend beyond the disclosure as filed – whether, as a result of the amendments, the claims are not clear and not supported – opposition unsuccessful – amendments are allowable – costs awarded.

Representation:  Patent attorney for the applicant:  Allens Patent & Trade Mark Attorneys

The Opponent did not appear or provide submissions for the hearing.

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Application:                2016251687

Title:RNA containing composition for treatment of tumor diseases

Patent Applicant:                   CureVac SE

Date of Decision:                   16 June 2023

DECISION

The amendments are allowable.  The opposition is unsuccessful. 

Costs according to Schedule 8 are awarded against the Opponent, BioNTech RNA Pharmaceuticals GmbH

REASONS FOR DECISION

  1. The present matter relates to Australian Application 2016251687 (the application) in the name of CureVac SE (the Applicant) and an opposition to an amendment under s104(4) of the Patents Act 1990 (Cth) (the Act) by BioNTech RNA Pharmaceuticals GmbH (the Opponent).

  2. The application was filed as International Patent Application PCT/EP2016/059109 on 22 April 2016 and published as WO2016/170176 on 27 October 2016. The application entered the national phase in Australia on 3 August 2017. The application was advertised as accepted on 11 June 2020. A notice of opposition to the grant of the patent under s59 of the Act was filed on 11 September 2020 (the S59 opposition).

  3. The Applicant filed a request to amend the specification on 20 July 2021 (the amendment).  Leave to amend was granted and the application for amendment advertised for opposition on 2 September 2021.  A notice of opposition to the amendment was filed by the Opponent on 1 November 2021 (the S104 opposition).  The present determination relates to the S104 opposition.

  4. A statement of grounds and particulars (SGP) was filed on 1 December 2021.  Both parties filed evidence in the opposition.  Evidence in Support was completed on 15 February 2022 and consisted of the following declarations:

    Cornelis J. M. Melief, dated 14 February 2022, and exhibits CJMM-12 to CJMM-14 (Melief 2)[1]

    Mark Edward Wickham, dated 15 February 2022, and exhibits MEW-1 to MEW-6 (Wickham)

    [1] Professor Melief had filed an earlier declaration in the S59 Opposition. I have included it in the present numbering of declarations as Melief 1.

  5. On 21 April 2022 the Applicant requested a direction by the Commissioner that the time to file their Evidence in Answer (EIA) be extended.  They subsequently filed their evidence on 20 May 2022.   This consisted of a declaration by Colin W. Pouton, dated 20 May 2022,…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read BioNTech RNA Pharmaceuticals GmbH v CureVac SE and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2023] APO 36
Decision Date

CaseChat Overview and Summary

The present matter concerns Australian Application 2016251687 for a patent in the name of CureVac SE (the Applicant) and an opposition to an amendment under section 104(4) of the Patents Act 1990 (Cth) (the Act) by BioNTech RNA Pharmaceuticals GmbH (the Opponent). The opposition was heard on 11 April 2023 by videoconference. The Opponent did not appear or provide submissions for the hearing. The Delegate, Dr Leslie F. McCaffery, found that the amendments are allowable, the opposition is unsuccessful, and costs are awarded against the Opponent. The Applicant filed a request to amend the specification on 20 July 2021, and leave to amend was granted. The application for amendment was advertised for opposition on 2 September 2021, and a notice of opposition to the amendment was filed by the Opponent on 1 November 2021. The grounds of opposition relied on by the Opponent are that the proposed amendment results in the specification claiming and disclosing matter that extends beyond that disclosed in the specification as filed, and that the specification would not comply with subsections 40(2) or (3) as a result of the amendment. The Delegate considered the legal principles and found that the amendment does not result in the specification claiming or disclosing matter that extends beyond that disclosed in the specification as filed, and that the amendment does not result in a lack of support. Therefore, the opposition is unsuccessful, and the amendments are allowable. Costs are awarded against the Opponent according to Schedule 8.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.